The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone
- PMID: 20563569
- DOI: 10.1007/s00228-010-0850-1
The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone
Abstract
Purpose: To evaluate the role of cytochrome 450 2D6 (CYP2D6) and ABCB1 variants on plasma risperidone concentrations and treatment response in 83 drug-naive patients experiencing a first episode of psychosis.
Methods: All patients were treated with risperidone for 8 weeks. The CYP2D6 genotyping was performed by allele-specific PCR-restriction fragment length polymorphism analysis (for alleles *3,*4,*6) and long-distance PCR (for duplications and allele *5), while real-time PCR analysis was used for the ABCB1 G2677T/A and C3435T variants. Plasma concentrations of risperidone and 9-OH risperidone were measured by high-performance liquid chromatography.
Results: The number of patients with the CYP2D6 wild type (wt)/wt, wt/mutation (mut) and mut/mut genotype was 43, 32 and 8, respectively. The number of patients with the ABCB1 2677G/G, G/T and T/T variants was 29, 42 and 12, respectively; those with the 3435CC, C/T and T/T variants was 25, 37 and 21, respectively. The CYP2D6 genotype had a strong effect on the steady-state dose-corrected plasma levels (C/D) of risperidone, its 9-OH metabolite and the active moiety, while the ABCB1 2677 T/T and 3435 T/T genotypes has similarly strong effects on the active moiety C/D. The CYP2D6 poor metabolizers had a significantly higher risperidone C/D and active moiety C/D and lower 9-OH risperidone C/D. The ABCB1 3435 T allele and the ABCB1 2667 T-3435 T haplotype carriers were more frequent among subjects without extrapyramidal syndromes. Patients showed significant improvements in positive and general symptoms, but not in negative symptoms. These changes were not related to variations in genetic and drug concentration data.
Conclusion: Our findings suggest that CYP2D6 and ABCB1 G2677T and C3435T may be useful determinants of risperidone plasma concentrations, but the clinical implications of these associations in relation to treatment response and side-effects remain unclear.
Similar articles
-
Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.Br J Pharmacol. 2011 Sep;164(2b):433-43. doi: 10.1111/j.1476-5381.2011.01385.x. Br J Pharmacol. 2011. PMID: 21449914 Free PMC article. Clinical Trial.
-
ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.Ther Drug Monit. 2008 Oct;30(5):628-33. doi: 10.1097/FTD.0b013e3181858ca9. Ther Drug Monit. 2008. PMID: 18708991
-
Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110241. doi: 10.1016/j.pnpbp.2020.110241. Epub 2021 Jan 2. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 33400943 Clinical Trial.
-
CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.Pharmacotherapy. 2020 Jul;40(7):632-647. doi: 10.1002/phar.2434. Epub 2020 Jul 12. Pharmacotherapy. 2020. PMID: 32519344
-
[Clinical pharmacogenetics in the treatment of schizophrenia].Nihon Shinkei Seishin Yakurigaku Zasshi. 2005 Jun;25(3):129-35. Nihon Shinkei Seishin Yakurigaku Zasshi. 2005. PMID: 16045195 Review. Japanese.
Cited by
-
CYP2D6 polymorphisms and their influence on risperidone treatment.Pharmgenomics Pers Med. 2016 Dec 1;9:131-147. doi: 10.2147/PGPM.S107772. eCollection 2016. Pharmgenomics Pers Med. 2016. PMID: 27942231 Free PMC article. Review.
-
ABCB1 variants and sex affect serotonin transporter occupancy in the brain.Mol Psychiatry. 2022 Nov;27(11):4502-4509. doi: 10.1038/s41380-022-01733-1. Epub 2022 Sep 7. Mol Psychiatry. 2022. PMID: 36071112 Free PMC article.
-
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Expert Opin Drug Metab Toxicol. 2022 Nov;18(11):769-785. doi: 10.1080/17425255.2022.2160317. Epub 2023 Jan 3. Expert Opin Drug Metab Toxicol. 2022. PMID: 36597259 Free PMC article. Review.
-
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Clin Pharmacokinet. 2015 Jul;54(7):709-35. doi: 10.1007/s40262-015-0267-1. Clin Pharmacokinet. 2015. PMID: 25860377 Review.
-
Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.Br J Pharmacol. 2011 Sep;164(2b):433-43. doi: 10.1111/j.1476-5381.2011.01385.x. Br J Pharmacol. 2011. PMID: 21449914 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous